GlycoNex (4168) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GlycoNex (4168) has a cash flow conversion efficiency ratio of -0.017x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-17.29 Million ≈ $-544.86K USD) by net assets (NT$1.01 Billion ≈ $31.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GlycoNex (4168) market capitalisation for the company's overall valuation and market capitalisation.
GlycoNex - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how GlycoNex's cash flow conversion efficiency has evolved over time, based on yearly financial data.
GlycoNex Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GlycoNex ranked by their cash flow conversion efficiency. Explore cash flow quality index of GlycoNex to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Adrad Holdings Ltd
AU:AHL
|
0.050x |
|
Lifetime Brands Inc
NASDAQ:LCUT
|
-0.120x |
|
mPLUS Corp
KQ:259630
|
-0.049x |
|
Lokesh Machines Limited
NSE:LOKESHMACH
|
-0.077x |
|
Jayant Agro Organics Limited
NSE:JAYAGROGN
|
-0.075x |
|
SMJ International Holdings Inc.
NYSE MKT:SMJF
|
N/A |
|
Alithya Group Inc
NASDAQ:ALYAF
|
-0.048x |
|
Hotron Precision Electronic Industrial Co Ltd
TW:3092
|
-0.046x |
Annual Cash Flow Conversion Efficiency for GlycoNex (2017–2024)
The table below shows the annual cash flow conversion efficiency of GlycoNex from 2017 to 2024. View GlycoNex (4168) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.05 Billion ≈ $32.97 Million |
NT$-221.97 Million ≈ $-6.99 Million |
-0.212x | -47.20% |
| 2023-12-31 | NT$1.28 Billion ≈ $40.21 Million |
NT$-183.92 Million ≈ $-5.79 Million |
-0.144x | -24.32% |
| 2022-12-31 | NT$1.45 Billion ≈ $45.54 Million |
NT$-167.55 Million ≈ $-5.28 Million |
-0.116x | -11.81% |
| 2021-12-31 | NT$1.36 Billion ≈ $42.81 Million |
NT$-140.86 Million ≈ $-4.44 Million |
-0.104x | -9.61% |
| 2020-12-31 | NT$1.54 Billion ≈ $48.51 Million |
NT$-145.59 Million ≈ $-4.59 Million |
-0.095x | +31.50% |
| 2019-12-31 | NT$1.30 Billion ≈ $40.98 Million |
NT$-179.58 Million ≈ $-5.66 Million |
-0.138x | -17.31% |
| 2018-12-31 | NT$1.53 Billion ≈ $48.28 Million |
NT$-180.34 Million ≈ $-5.68 Million |
-0.118x | -452.73% |
| 2017-12-31 | NT$1.84 Billion ≈ $58.01 Million |
NT$61.43 Million ≈ $1.94 Million |
0.033x | -- |
About GlycoNex
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company's development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under preclinical stage; GNX203, glycan-directed anti… Read more